1. Home
  2. BUDA vs LIXT Comparison

BUDA vs LIXT Comparison

Compare BUDA & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BUDA

Buda Juice Inc. Common Stock

N/A

Current Price

$10.79

Market Cap

91.7M

ML Signal

N/A

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$7.10

Market Cap

107.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUDA
LIXT
Founded
2013
2005
Country
United States
United States
Employees
39
3
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.7M
107.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BUDA
LIXT
Price
$10.79
$7.10
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$14.00
N/A
AVG Volume (30 Days)
20.9K
594.5K
Earning Date
03-26-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.25
$2.45
52 Week High
$12.00
$8.38

Technical Indicators

Market Signals
Indicator
BUDA
LIXT
Relative Strength Index (RSI) 63.66 54.53
Support Level $8.21 $6.21
Resistance Level N/A $7.64
Average True Range (ATR) 0.82 0.84
MACD 0.26 -0.05
Stochastic Oscillator 64.00 53.35

Price Performance

Historical Comparison
BUDA
LIXT

About BUDA Buda Juice Inc. Common Stock

Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.

Share on Social Networks: